Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Metabolite profiling identifies markers of uremia.

Rhee EP, Souza A, Farrell L, Pollak MR, Lewis GD, Steele DJ, Thadhani R, Clish CB, Greka A, Gerszten RE.

J Am Soc Nephrol. 2010 Jun;21(6):1041-1051. doi: 10.1681/ASN.2009111132. Epub 2010 Apr 8.

2.

Effect of diabetes on uremic dyslipidemia.

Kimoto E, Shoji T, Emoto M, Miki T, Tabata T, Okuno Y, Ishimura E, Inaba M, Nishizawa Y.

J Atheroscler Thromb. 2002;9(6):305-13.

3.

Cardiovascular risk factors in hemodialysis and peritoneal dialysis patients.

Helal I, Smaoui W, Hamida FB, Ouniss M, Aderrahim E, Hedri H, Elyounsi F, Maiz HB, Abdallah TB, Kheder A.

Saudi J Kidney Dis Transpl. 2010 Jan;21(1):59-62.

4.

Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study.

Niewczas MA, Sirich TL, Mathew AV, Skupien J, Mohney RP, Warram JH, Smiles A, Huang X, Walker W, Byun J, Karoly ED, Kensicki EM, Berry GT, Bonventre JV, Pennathur S, Meyer TW, Krolewski AS.

Kidney Int. 2014 May;85(5):1214-24. doi: 10.1038/ki.2013.497. Epub 2014 Jan 15.

5.

A plasma long-chain acylcarnitine predicts cardiovascular mortality in incident dialysis patients.

Kalim S, Clish CB, Wenger J, Elmariah S, Yeh RW, Deferio JJ, Pierce K, Deik A, Gerszten RE, Thadhani R, Rhee EP.

J Am Heart Assoc. 2013 Dec 5;2(6):e000542. doi: 10.1161/JAHA.113.000542.

6.

Optimized metabolomic approach to identify uremic solutes in plasma of stage 3-4 chronic kidney disease patients.

Mutsaers HA, Engelke UF, Wilmer MJ, Wetzels JF, Wevers RA, van den Heuvel LP, Hoenderop JG, Masereeuw R.

PLoS One. 2013 Aug 2;8(8):e71199. doi: 10.1371/journal.pone.0071199. Print 2013.

7.

Effects of dialysis purity on uremic dyslipidemia.

Schiffl H, Lang SM.

Ther Apher Dial. 2010 Feb;14(1):5-11. doi: 10.1111/j.1744-9987.2009.00713.x.

PMID:
20438514
8.

Mass spectrometric monitoring of albumin in uremia.

Thornalley PJ, Argirova M, Ahmed N, Mann VM, Argirov O, Dawnay A.

Kidney Int. 2000 Nov;58(5):2228-34.

9.

4-Pyridone-3-carboxamide-1-β-D-ribonucleoside triphosphate (4PyTP), a novel NAD metabolite accumulating in erythrocytes of uremic children: a biomarker for a toxic NAD analogue in other tissues?

Synesiou E, Fairbanks LD, Simmonds HA, Slominska EM, Smolenski RT, Carrey EA.

Toxins (Basel). 2011 Jun;3(6):520-37. doi: 10.3390/toxins3060520. Epub 2011 Jun 7.

10.
11.

[A gas chromatographic-mass spectrometric analysis of organic acids in uremic ultrafiltrate (author's transl)].

Maeda K, Niwa T, Kobayashi K.

Nihon Jinzo Gakkai Shi. 1981 Jan;23(1):75-88. Japanese. No abstract available.

PMID:
7289205
12.

Lipid-lowering effect of carnitine in chronically uremic patients treated with maintenance hemodialysis.

Guarnieri GF, Ranieri F, Toigo G, Vasile A, Ciman M, Rizzoli V, Moracchiello M, Campanacci L.

Am J Clin Nutr. 1980 Jul;33(7):1489-92.

PMID:
7395772
14.

Insulin resistance in dialysis versus non dialysis end stage renal disease patients without diabetes.

Satirapoj B, Supasyndh O, Phantana-Angkul P, Ruangkanchanasetr P, Nata N, Chaiprasert A, Kanjanakul I, Choovichian P.

J Med Assoc Thai. 2011 Sep;94 Suppl 4:S87-93.

PMID:
22043573
15.

Red blood cell calcium homeostasis in patients with end-stage renal disease.

Gafter U, Malachi T, Barak H, Djaldetti M, Levi J.

J Lab Clin Med. 1989 Sep;114(3):222-31.

PMID:
2527934
16.

Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: correlation with low molecular AGE adduct clearance.

Gugliucci A, Mehlhaff K, Kinugasa E, Ogata H, Hermo R, Schulze J, Kimura S.

Clin Chim Acta. 2007 Feb;377(1-2):213-20. Epub 2006 Oct 11.

PMID:
17118352
17.

Coenzyme Q10 levels, plasma lipids and peroxidation extent in renal failure and in hemodialytic patients.

Lippa S, Colacicco L, Callà C, Sagliaschi G, Angelitti AG.

Mol Aspects Med. 1994;15 Suppl:s213-9.

PMID:
7752833
18.

Association between uremic toxins and depression in patients with chronic kidney disease undergoing maintenance hemodialysis.

Hsu HJ, Yen CH, Chen CK, Wu IW, Lee CC, Sun CY, Chang SJ, Chou CC, Hsieh MF, Chen CY, Hsu CY, Tsai CJ, Wu MS.

Gen Hosp Psychiatry. 2013 Jan-Feb;35(1):23-7. doi: 10.1016/j.genhosppsych.2012.08.009. Epub 2012 Oct 6. Erratum in: Gen Hosp Psychiatry. 2013 Jul-Aug;35(4):450.

PMID:
23044245
19.

Mechanisms of uremic erythrocyte-induced adhesion of human monocytes to cultured endothelial cells.

Pandolfi A, Di Pietro N, Sirolli V, Giardinelli A, Di Silvestre S, Amoroso L, Di Tomo P, Capani F, Consoli A, Bonomini M.

J Cell Physiol. 2007 Dec;213(3):699-709.

PMID:
17516566
20.

The advanced glycation endproduct pentosidine and monocyte activation in uremia.

Friedlander MA, Witko-Sarsat V, Nguyen AT, Wu YC, Labrunte M, Verger C, Jungers P, Descamps-Latscha B.

Clin Nephrol. 1996 Jun;45(6):379-82.

PMID:
8793229
Items per page

Supplemental Content

Write to the Help Desk